153
Participants
Start Date
May 31, 2018
Primary Completion Date
January 14, 2021
Study Completion Date
August 5, 2022
Alirocumab SAR236553 (REGN727)
Pharmaceutical form:solution Route of administration: subcutaneous injection
Rosuvastatin
Pharmaceutical form:tablet Route of administration: oral
Atorvastatin
Pharmaceutical form:Tablet Route of administration: Oral
Simvastatin
Pharmaceutical form:Tablet Route of administration: Oral
Pravastatin
Pharmaceutical form:Tablet Route of administration: Oral
Lovastatin
Pharmaceutical form:Tablet Route of administration: Oral
Fluvastatin
Pharmaceutical form:Capsule Route of administration: Oral
Ezetimibe
Pharmaceutical form:Tablet Route of administration: Oral
Cholestyramine
Pharmaceutical form:oral suspension Route of administration: oral
Nicotinic acid
Pharmaceutical form:Tablet Route of administration: Oral
Fenofibrate
Pharmaceutical form:Tablet Route of administration: Oral
Omega-3 fatty acids
Pharmaceutical form:capsule Route of administration: oral
Placebo
Pharmaceutical form:solution Route of administration: subcutaneous injection
Investigational Site Number :1580001, Taipei
Investigational Site Number :7050001, Ljubljana
Investigational Site Number :0400001, Vienna
Investigational Site Number :3480001, Budapest
Investigational Site Number :2080001, Copenhagen
Investigational Site Number :1000002, Plovdiv
Investigational Site Number :7100002, Parow
Investigational Site Number :7240002, A Coruña
Investigational Site Number :2030001, Praha 5 - Motol
Investigational Site Number :3800003, Milan
Presbyterian Novant Heart & Wellness-Site Number:8400002, Charlotte
Investigational Site Number :7240003, Pamplona
Excel Medical Clinical Trials, LLC-Site Number:8400001, Boca Raton
Investigational Site Number :7920001, Izmir
Vanderbilt University-Site Number:8400003, Nashville
Investigational Site Number :2500002, Nantes
Investigational Site Number :4840008, Guadalajara
Cincinnati Children's Hospital Medical Center-Site Number:8400005, Cincinnati
Investigational Site Number :2030002, Brno
Washington University School of Medicine-Site Number:8400006, St Louis
Investigational Site Number :4840007, Oaxaca City
Investigational Site Number :2500001, Bron
Investigational Site Number :3800001, Palermo
Investigational Site Number :6430004, Moscow
Investigational Site Number :6430006, Kazan'
Investigational Site Number :6430002, Ufa
Investigational Site Number :6430001, Kemerovo
Investigational Site Number :0320001, Buenos Aires
Investigational Site Number :0760004, Porto Alegre
Investigational Site Number :0760001, São Paulo
Investigational Site Number :1240001, Québec
Investigational Site Number :2460001, HUS
Investigational Site Number :3800002, Roma
Investigational Site Number :4220001, Beirut
Investigational Site Number :5780001, Oslo
Investigational Site Number :6160002, Gdansk
Investigational Site Number :4220003, Room Hospital Street, Achrafie
Investigational Site Number :5280001, Amsterdam
Investigational Site Number :6160001, Lodz
Investigational Site Number :7240004, Badalona
Investigational Site Number :7240001, Barcelona
Investigational Site Number :7520001, Stockholm
Investigational Site Number :7920002, Ankara
Lead Sponsor
Regeneron Pharmaceuticals
INDUSTRY
Sanofi
INDUSTRY